Melqart Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Melqart Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-172,949	Closed	-$14.2M	–	55
2024 Q2	$14.2M	Buy	+172,949	New	+$14.4M	1.18%	27
2022 Q4	–	Sell	-155,849	Closed	-$13.2M	–	41
2022 Q3	$13.2M	Sell	155,849 -11,012	-7%	-$981K	1.01%	42
2022 Q2	$13.8M	Sell	166,861 -163,401	-49%	-$13M	1.07%	33
2022 Q1	$25.5M	Sell	330,262 -173,357	-34%	-$14.5M	1.7%	23
2021 Q4	$44.5M	Sell	503,619 -99,181	-16%	-$8.18M	2.26%	10
2021 Q3	$46.6M	Buy	602,800 +152,000	+34%	+$12M	2.23%	14
2021 Q2	$37.6M	Buy	450,800 +123,000	+38%	+$9.75M	1.69%	20
2021 Q1	$24.8M	Buy	+327,800	New	+$26.8M	1.12%	25

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Melqart Asset Management's BMRN Position: Q3 2024 in Review

Melqart Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 172,949 shares — an estimated $14.2M sold.

Melqart Asset Management first reported a position in BMRN in Q1 2021 and held it in 8 quarters. The position peaked at $46.6M in Q3 2021. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Melqart Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Melqart Asset Management sold 172,949 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $14.2M.
Melqart Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Melqart Asset Management's BioMarin Pharmaceuticals position peaked at $46.6M in Q3 2021.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Melqart Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.